Literature DB >> 3484381

Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice.

M J Ehrke, D Maccubbin, K Ryoyama, S A Cohen, E Mihich.   

Abstract

Based on the observation that spleen cells from Adriamycin-treated mice could develop augmented levels of cytotoxic T-lymphocyte activity in response to heat-treated and/or X-irradiated alloantigens, it was postulated that modulations in soluble mediators could be involved in this phenomenon. In fact, in this study Adriamycin-induced increases in the levels of prostaglandin E2 and interleukin 2 activity have been observed with isolated cells. The "interleukin 2-like" activity was indistinguishable from that of partially purified interleukin 2 in terms of ability to restore responsiveness to experimentally inhibited primary alloantigen response cultures and to maintain long-term cultures of activated T-cells. Furthermore this latter activity was completely ablated by antiinterleukin 2 monoclonal antibody. While the modification in prostaglandin E2 production did not appear to play a role in determining augmentation of cytotoxic T-cell activity, the modification in interleukin 2 production was consistent with the possibility that this is a primary mechanism of Adriamycin-induced augmented cell-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484381

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo.

Authors:  M Micallef; M Hosokawa; T Shibata; A Nakane; Z B Yang; T Minagawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  4'-O-tetrahydropyranyl adriamycin (THP-ADM)-induced modifications of murine peritoneal macrophages.

Authors:  A Bravo-Cuellar; G Mathé; S Orbach-Arbouys
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Glycosidically bound sialic acid levels as a predictive marker of postoperative adjuvant therapy in gastric cancer.

Authors:  K Ogoshi; Y Kondoh; T Tajima; T Mitomi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions.

Authors:  D L Maccubbin; S A Cohen; M J Ehrke
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 5.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

6.  Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C.

Authors:  T Akiyoshi; S Arinaga; H Tsuji
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 7.  [Mitoxanthrone in the therapy of multiple sclerosis].

Authors:  B C Kieseier; R Gold; H-P Hartung
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

8.  Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.

Authors:  L Gorelik; A Prokhorova; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

9.  Cytolytic T lymphocytes and antibodies to myocytes in adriamycin-treated BALB/c mice. Evidence for immunity to drug-induced antigens.

Authors:  S A Huber; A Moraska
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

10.  Immunodepressive activity of FCE 23762 on humoral and cell-mediated immune responses in normal mice: comparison with doxorubicin.

Authors:  M C Fornasiero; M Ferrari; P Gnocchi; D Trizio; A M Isetta
Journal:  Agents Actions       Date:  1992-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.